Skip to content

To see the effect of Ayurvedic medicines (Pushyanuga churna and Usheerasava) in treating excessive and irregular menses.

Clinical evaluation of the efficacy of Pushyanuga churna and Usheerasava in the management of Abnormal uterine bleeding(Asrigdara)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/06/019802
Enrollment
80
Registered
2019-06-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N939- Abnormal uterine and vaginal bleeding, unspecified

Interventions

Intervention1: Pushyanuga churna and usheerasava: Pushyanuga churna: Dose:3gm with tandulodaka anupaan (192 ml)before meals Frequency: Twice a day Route of administration: oral Duration: 90 days Ush

Sponsors

CCRAS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Excessive bleeding during menstruation (menstrual blood loss > 80 ml in 1-7 days) having score more than 100 points on Pictorial Blood Loss Assessment Chart (PBLAC) for 3 consecutive cycles or Prolonged menstrual bleeding (more than >7days) for 3 consecutive cycles or Frequent menses with interval of menstrual cycle 2)Patient willing to participate for three months after written informed consent. 3)Hemoglobin more than or equal to 7 gm%.

Exclusion criteria

Exclusion criteria: 1)Patients having pelvic pathologies like Polyp, Adenomyosis, Leiomyoma, Malignancy and Hyperplasia and Cervical erosion. 2)Other causes of excessive menstrual bleeding like Intra Uterine Contraceptive Devices and thyroid dysfunction. 3)Blood Dyscrasias; diseases of platelets, clotting factors, diseases of RBCs and WBCs. 4)Incomplete abortion

Design outcomes

Primary

MeasureTime frame
Changes in clinical features of Abnormal Uterine Bleeding using Pictorial Blood loss Assessment Chart scoreTimepoint: Baseline, 15th, 30th, 45th, 60th, 75th, 90th, 120th day

Secondary

MeasureTime frame
Changes in PGWBI of subjectsTimepoint: Baseline, 90th day and 120th day

Countries

India

Contacts

Public ContactDr Anubha Chandla

RARIND/CCRAS

anubhachandla.info@gmail.com7508049506

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026